Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Agios Pharmaceuticals (AGIO) over the last 8 years, with Q3 2025 value amounting to $43000.0.

  • Agios Pharmaceuticals' Change in Receivables rose 10667.7% to $43000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year decrease of 159.63%. This contributed to the annual value of $1.3 million for FY2024, which is 11506.62% up from last year.
  • Latest data reveals that Agios Pharmaceuticals reported Change in Receivables of $43000.0 as of Q3 2025, which was up 10667.7% from $1.6 million recorded in Q2 2025.
  • In the past 5 years, Agios Pharmaceuticals' Change in Receivables ranged from a high of $8.1 million in Q2 2021 and a low of -$7.0 million during Q4 2021
  • Over the past 5 years, Agios Pharmaceuticals' median Change in Receivables value was $348500.0 (recorded in 2022), while the average stood at $279388.9.
  • Data for Agios Pharmaceuticals' Change in Receivables shows a peak YoY increase of 43139.16% (in 2025) and a maximum YoY decrease of 21897.36% (in 2025) over the last 5 years.
  • Quarter analysis of 5 years shows Agios Pharmaceuticals' Change in Receivables stood at -$7.0 million in 2021, then surged by 105.55% to $388000.0 in 2022, then surged by 321.13% to $1.6 million in 2023, then plummeted by 39.35% to $991000.0 in 2024, then plummeted by 95.66% to $43000.0 in 2025.
  • Its last three reported values are $43000.0 in Q3 2025, $1.6 million for Q2 2025, and -$765000.0 during Q1 2025.